Most Cited Papers In Last Two Years

Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects

A multimodal neuroimaging and hepatic imaging analysis for hepatic-type and neurological-type Wilson’s disease

Accelerated biological aging drives the progression from MASLD to cirrhosis

Associations of estimated pulse wave velocity with cardiovascular-kidney-metabolic syndrome in U.S. adults: the role of sex and ethnicity (NHANES 1999-2018)

Medium-chain phosphatidylcholine (MCPC) as a putative option for suppressing hepatocellular inflammation in cholestatic conditions and steatotic liver diseases

The cumulative effect and sensitive period of overweight/obesity on high blood pressure in children based on the Tianjin Birth Cohort Study

Short-term L-arabinose administration alleviates MASLD by remodeling gut microbiota and activating hepatic ATF5-dependent mitochondrial unfolded protein response

Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions

Prevalence and incidence of obesity among children and adolescents in Guangdong: a prospective analysis from 2019-2022

Beyond the liver: targeting the hepatic microenvironment and multi-organ networks for innovative MASH therapy

Association between wearable device usage and obesity transition in children and adolescents: a nationwide longitudinal study

Surgical approaches to diabetic foot ulcers: an algorithm for applying the reconstructive ladder

Liver fibrosis and diabetic peripheral neuropathy in individuals with type 2 diabetes mellitus: an observational, cross-sectional study

The emerging pathological mechanism of coronary microvascular dysfunction: a narrative review

Histopathological characteristics in livers of deceased patients with COVID-19

The cross-talk between neurodegeneration and metabolic disorders

Research and clinical trial design in patients with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD): a narrative review

Evolving trends and drug class dynamics in drug-induced fatty liver disease over two decades